Analysts expect Genocea Biosciences Inc (NASDAQ:GNCA) to announce earnings of ($0.41) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.51) to ($0.36). Genocea Biosciences reported earnings per share of ($0.88) in the same quarter last year, which suggests a positive year-over-year growth rate of 53.4%. The firm is scheduled to report its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that Genocea Biosciences will report full year earnings of ($2.00) per share for the current fiscal year, with EPS estimates ranging from ($2.13) to ($1.91). For the next financial year, analysts expect that the firm will report earnings of ($1.60) per share, with EPS estimates ranging from ($1.87) to ($1.12). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.17.

GNCA has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a research note on Thursday, October 24th. HC Wainwright restated a “buy” rating on shares of Genocea Biosciences in a research note on Monday, November 11th. Svb Leerink assumed coverage on shares of Genocea Biosciences in a research note on Friday, November 15th. They set an “outperform” rating and a $7.00 price objective for the company. Leerink Swann assumed coverage on shares of Genocea Biosciences in a research note on Friday, November 15th. They set an “outperform” rating for the company. Finally, ValuEngine upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $12.94.

Institutional investors have recently bought and sold shares of the company. Morgan Stanley acquired a new position in shares of Genocea Biosciences during the 2nd quarter worth about $26,000. Wedbush Securities Inc. acquired a new stake in Genocea Biosciences in the 4th quarter valued at about $40,000. Cubist Systematic Strategies LLC acquired a new stake in Genocea Biosciences in the 2nd quarter valued at about $40,000. Citadel Advisors LLC acquired a new stake in Genocea Biosciences in the 2nd quarter valued at about $68,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in Genocea Biosciences in the 2nd quarter valued at about $84,000. Institutional investors own 54.93% of the company’s stock.

NASDAQ GNCA traded down $0.15 on Friday, reaching $2.58. The company had a trading volume of 290,104 shares, compared to its average volume of 165,863. The firm has a market capitalization of $71.39 million, a price-to-earnings ratio of -1.36 and a beta of 2.32. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.33 and a current ratio of 4.33. Genocea Biosciences has a 1-year low of $1.99 and a 1-year high of $11.28. The company’s fifty day moving average is $2.23 and its 200-day moving average is $2.84.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Read More: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.